(Total Views: 1152)
Posted On: 11/07/2021 11:21:42 AM
Post# of 72440
Many people on this board took a significant haircut on Friday which is something that none of us want to see happen. The truth however, is that paper losses do not matter if you understand that IPIX share price (SP) is a meaningless number in the short term. The reason for this is that IPIX SP is priced at whatever the criminal cabal wants it to be in the short term. If news is successful this week there will be a new and much larger investor base that will want to own a piece of the new Covid-killer. The cost to the criminals to continue to compress IPIX SP artificially downward will increase dramatically. There is a big difference between claiming an excuse of why something happened versus the reason something actually did happen.
The Pfizer drug is very similar to the Merck drug as they are both Protease inhibitors which were designed for HIV/AIDS treatment. The Merck drug is mutagenic. It was designed to introduce errors into genetic code. What could possibly go wrong with that approach? The Merck drug failed efficacy in an FDA trial for Moderate/Severe so they are now positioning it as an early treatment for Mild Covid. Remember there are 4 classifications of CV19 disease progression. Mild, Moderate, Severe and Critical. Both the Pfizer and Merck drugs are targeted for Mild Covid and because of their size and clout, they will both probably sell billions of their pills as they fight each other for the non-hospitalized CV19 treatment market. They have a desirable delivery system via a pill but as I have mentioned before, so does cyanide. Neither of these 2 IMO are any better than Ivermectin which Merck marketed until their patent expired. They have questionable efficacy and even more questionable safety profiles.
The Pfizer drug Paxlovid (PF-07321332; Ritonavir) can cause serious, life-threatening side effects including inflammation of the pancreas (pancreatitis), heart rhythm problems, severe skin rash and allergic reactions, liver problems, and drug interactions. You probably won’t hear about this from the talking heads on TV but you will hear them parrot the term “game-changer”.
All of the above mentioned antivirals as well as remdesivir, have efficacy benefits if you take them early in the disease progression but NONE of them are effective once a patient gets hospitalized. NONE of these antivirals kill Covid but they do help limit viral load increases if treatment is given in the first couple of days of disease.
Brilacidin is being positioned to treat HOSPITALIZED patients with the current trial targeted for Moderate/ Severe patients and the FDA approved Compassionate Use (CU) protocol for Critical patients. Brilacidin has multiple mechanism of action (MOA) properties as it targets both the virus and host cell. Brilacidin has virucidal activity and blocks viral attachment to host cells. Brilacidin has broad-spectrum antiviral activity and its MOA inhibition is not cell type dependent.
I believe that there is an excellent chance that Brilacidin will show success in both trial data and CU. Once Brilacidin becomes the gold standard for treatment of hospitalized CV19 patients, IMO a BP partner will want to expand Brilacidin’s position from the CV19 hospitalized market to include the non-hospitalized Mild market for CV19 as well as many other Viruses and Infections. IMO they will quickly develop an inhaler, depo or other easily administered patient delivery. Success in CU would be a godsend to save lives in Severe/Critical patients. CU success could very well be the milestone that prompts the FDA to approve Brilacidin to get Emergency Use Authorization so that patients in need have a more streamlined process to get the treatment needed.
The EXCUSE for the IPIX share price (SP) compression on Friday was the Pfizer announcement. The real REASON for the SP decrease is that the criminal hedge funds and their cabal control IPIX SP and won’t begin to lose that control until IPIX is listed on NASDAQ which I would guesstimate will take place 1H 2022. Does that mean the criminals will go away once IPIX is up-listed? No, unfortunately they will be around until they have to cover their entire position which will not take place until IPIX is bought out by a much larger entity a few years down the road. IMO the criminals will however, initiate the covering of their butts leading up to Up-listing. In the meantime IPIX SP will zig-zag upwards due to new investor demand starting with CV19 trial & CU results and subsequent funding. Up-listing will trigger institutional investment dollars which will drive up SP with legitimate volume. IMO we will see many more trading days like Friday with big hits to SP but if milestones continue to be met, the SP will climb significantly on a month to month basis. There will be crazy day to day ups and downs as the criminals try to encourage and condition investors to sell them IPIX shares that the criminals desperately need to cover their extremely deep Naked Short Selling (NSS) hole that they have dug for themselves.
Fasten your harness and seatbelt and hang on tightly to your restraint for a fun and rewarding upcoming ride which will start any day now!
The Pfizer drug is very similar to the Merck drug as they are both Protease inhibitors which were designed for HIV/AIDS treatment. The Merck drug is mutagenic. It was designed to introduce errors into genetic code. What could possibly go wrong with that approach? The Merck drug failed efficacy in an FDA trial for Moderate/Severe so they are now positioning it as an early treatment for Mild Covid. Remember there are 4 classifications of CV19 disease progression. Mild, Moderate, Severe and Critical. Both the Pfizer and Merck drugs are targeted for Mild Covid and because of their size and clout, they will both probably sell billions of their pills as they fight each other for the non-hospitalized CV19 treatment market. They have a desirable delivery system via a pill but as I have mentioned before, so does cyanide. Neither of these 2 IMO are any better than Ivermectin which Merck marketed until their patent expired. They have questionable efficacy and even more questionable safety profiles.
The Pfizer drug Paxlovid (PF-07321332; Ritonavir) can cause serious, life-threatening side effects including inflammation of the pancreas (pancreatitis), heart rhythm problems, severe skin rash and allergic reactions, liver problems, and drug interactions. You probably won’t hear about this from the talking heads on TV but you will hear them parrot the term “game-changer”.
All of the above mentioned antivirals as well as remdesivir, have efficacy benefits if you take them early in the disease progression but NONE of them are effective once a patient gets hospitalized. NONE of these antivirals kill Covid but they do help limit viral load increases if treatment is given in the first couple of days of disease.
Brilacidin is being positioned to treat HOSPITALIZED patients with the current trial targeted for Moderate/ Severe patients and the FDA approved Compassionate Use (CU) protocol for Critical patients. Brilacidin has multiple mechanism of action (MOA) properties as it targets both the virus and host cell. Brilacidin has virucidal activity and blocks viral attachment to host cells. Brilacidin has broad-spectrum antiviral activity and its MOA inhibition is not cell type dependent.
I believe that there is an excellent chance that Brilacidin will show success in both trial data and CU. Once Brilacidin becomes the gold standard for treatment of hospitalized CV19 patients, IMO a BP partner will want to expand Brilacidin’s position from the CV19 hospitalized market to include the non-hospitalized Mild market for CV19 as well as many other Viruses and Infections. IMO they will quickly develop an inhaler, depo or other easily administered patient delivery. Success in CU would be a godsend to save lives in Severe/Critical patients. CU success could very well be the milestone that prompts the FDA to approve Brilacidin to get Emergency Use Authorization so that patients in need have a more streamlined process to get the treatment needed.
The EXCUSE for the IPIX share price (SP) compression on Friday was the Pfizer announcement. The real REASON for the SP decrease is that the criminal hedge funds and their cabal control IPIX SP and won’t begin to lose that control until IPIX is listed on NASDAQ which I would guesstimate will take place 1H 2022. Does that mean the criminals will go away once IPIX is up-listed? No, unfortunately they will be around until they have to cover their entire position which will not take place until IPIX is bought out by a much larger entity a few years down the road. IMO the criminals will however, initiate the covering of their butts leading up to Up-listing. In the meantime IPIX SP will zig-zag upwards due to new investor demand starting with CV19 trial & CU results and subsequent funding. Up-listing will trigger institutional investment dollars which will drive up SP with legitimate volume. IMO we will see many more trading days like Friday with big hits to SP but if milestones continue to be met, the SP will climb significantly on a month to month basis. There will be crazy day to day ups and downs as the criminals try to encourage and condition investors to sell them IPIX shares that the criminals desperately need to cover their extremely deep Naked Short Selling (NSS) hole that they have dug for themselves.
Fasten your harness and seatbelt and hang on tightly to your restraint for a fun and rewarding upcoming ride which will start any day now!
(27)
(1)Scroll down for more posts ▼
